Kinetics, Prognostic and Predictive Values of ESR1 Circulating Mutations in Metastatic Breast Cancer Patients Progressing on Aromatase Inhibitor

Oncotarget - United States
doi 10.18632/oncotarget.12950
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy

Cancers
Cancer ResearchOncology
2019English

Guidelines for Osteoprotection in Breast Cancer Patients on an Aromatase Inhibitor

Breast Care
SurgeryOncology
2010English

Unraveling the Clinicopathological Features Driving the Emergence of ESR1 Mutations in Metastatic Breast Cancer

npj Breast Cancer
OncologyRadiologyNuclear MedicinePharmacologyImaging
2018English

Analysis of ESR1 Mutation in Circulating Tumor DNA Demonstrates Evolution During Therapy for Metastatic Breast Cancer

Science Translational Medicine
Medicine
2015English

Prognostic Markers and Tumour Growth Kinetics in Melanoma Patients Progressing on Vemurafenib

Melanoma Research
DermatologyCancer ResearchOncology
2016English

Establishment and Validation of Circulating Tumor Cell-Based Prognostic Nomograms in First-Line Metastatic Breast Cancer Patients

Clinical Cancer Research
Cancer ResearchOncology
2013English

Prognostic and Predictive Values of the Immunoscore in Patients With Rectal Cancer

Clinical Cancer Research
Cancer ResearchOncology
2014English

Accumulation of P53 Is Prognostic for Aromatase Inhibitor Resistance in Early-Stage Postmenopausal Patients With ER-positive Breast Cancer

OncoTargets and Therapy
OncologyPharmacology
2015English

An 8-Gene mRNA Expression Profile in Circulating Tumor Cells Predicts Response to Aromatase Inhibitors in Metastatic Breast Cancer Patients

BMC Cancer
Cancer ResearchOncologyGenetics
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy